1. What Makes Structured Products Different from Conventional Securities?
Structured products differ fundamentally because they embed derivative contracts within debt or equity wrappers, meaning the investor's return depends on the performance of underlying reference assets rather than on coupon payments or equity appreciation alone. This embedded leverage and optionality create legal exposures that conventional equity or bond investors do not typically encounter. A structured investment products attorney focuses on these specific mechanics and the contractual language that defines how payoffs are calculated, what happens if the reference asset becomes illiquid, and how counterparty credit risk affects your position.
How Do Counterparty and Credit Exposures Work in Structured Products?
In a structured product, the investor often holds an unsecured claim against the issuer or intermediary, meaning if that entity becomes insolvent, recovery may be limited or eliminated entirely. The prospectus typically discloses the issuer's credit rating, but that rating reflects general creditworthiness, not the issuer's ability to pay off complex derivative positions if markets move dramatically. Courts have recognized that structured product investors bear this counterparty risk as part of the bargained-for terms, and disputes over whether the issuer adequately disclosed this risk have become increasingly contested in New York federal courts, where many structured product disputes are litigated under the Securities Act and common law fraud standards.
2. When Should an Investor Consult a Structured Products Attorney?
An investor should engage a structured products attorney before committing capital, during the due diligence phase if the product terms are non-standard, and immediately if performance diverges from what the marketing materials suggested or if the issuer experiences financial distress. Early consultation can clarify whether the suitability and disclosure obligations imposed on the broker or advisor were satisfied, and whether the product's actual mechanics align with your risk tolerance and investment objectives. Waiting until a loss occurs often forecloses remedies that depend on timely notice or preservation of claims.
What Documentation Should Investors Preserve from the Outset?
Preserve all marketing materials, term sheets, prospectuses, confirmations, and any communications with the broker or advisor that describe the product's features, risks, or expected outcomes. In disputes over suitability or disclosure, New York courts and arbitration panels rely heavily on contemporaneous written records to determine what the investor knew and was told at the time of purchase. If the broker's oral representations differ from the written term sheet, that discrepancy becomes critical evidence. Investors should also maintain records of any follow-up conversations or emails questioning the product's performance or requesting clarification on terms, because these contemporaneous concerns can support claims that risks were not adequately explained.
3. What Are the Key Legal Standards Governing Structured Product Sales?
Brokers and advisors selling structured products must comply with suitability rules under FINRA regulations and, in some cases, fiduciary obligations if the advisor is registered as an investment adviser under the Investment Advisers Act. Suitability requires that the product be appropriate for the investor's financial situation, investment experience, and objectives, not merely that it be profitable for the broker. Courts have found that recommending a complex structured product to an unsophisticated investor without demonstrating the investor's understanding of the leverage, optionality, and counterparty risk can violate suitability standards, even if the product performed as designed.
How Do Disclosure Obligations Protect Investors in Structured Products?
Issuers and brokers must disclose material risks, including the mechanics of the embedded derivatives, the conditions under which the product may become illiquid, and the creditworthiness of the counterparties backing the payoff. Disclosure defects that obscure these risks, such as burying them in footnotes, using technical jargon without explanation, or presenting risk in a way that minimizes its practical impact, can create liability under federal securities laws and state common law fraud standards. The challenge for investors is that structured product prospectuses are often lengthy and technical, and courts have sometimes held that even detailed disclosure does not satisfy the legal standard if the disclosure fails to communicate the true nature or magnitude of the risk in language a reasonable investor could understand.
4. What Remedies and Procedural Options Are Available to Investors?
Investors harmed by structured product sales may pursue claims for breach of suitability, negligent misrepresentation, fraud, or breach of contract, depending on the facts and the terms of the customer agreement. Most brokerage and advisory agreements contain arbitration clauses that require disputes to be resolved through FINRA arbitration rather than litigation. Arbitration can be faster and more private than court proceedings, but it also limits appeal rights and may result in less transparent decision-making compared to federal court litigation under the Securities Act and Exchange Act.
What Steps Should Investors Take before a Dispute Becomes Contentious?
Document the investment process thoroughly: record the dates and substance of conversations with the broker or advisor, retain all written materials received, and create a contemporaneous written summary of any oral representations about the product's performance, risks, or suitability for your portfolio. If you discover that the product's performance diverges from expectations or that the broker's representations appear inconsistent with the prospectus, send a written inquiry to the broker requesting clarification and preserving your concerns in the record. This contemporaneous record-making becomes essential in arbitration or litigation because it demonstrates that you raised concerns promptly and did not wait until losses mounted to assert claims. In New York arbitration proceedings, arbitrators often weight the timeliness and specificity of investor objections when evaluating suitability and disclosure claims.
| Key Consideration | Why It Matters for Investors |
| Counterparty Credit Risk | Your return depends on the issuer remaining solvent; insolvency may eliminate recovery entirely. |
| Embedded Leverage and Optionality | These features amplify gains and losses; they require sophisticated understanding to evaluate suitability. |
| Liquidity Constraints | Structured products may not be tradeable before maturity; early exit may require paying a bid-ask spread to the issuer. |
| Suitability Documentation | Brokers must have records showing the product was appropriate for your experience and objectives; absence of suitability documentation strengthens investor claims. |
| Arbitration vs. Litigation | Most agreements require arbitration, which is faster but offers fewer appeal rights than court proceedings. |
Engaging a structured products attorney early, before or immediately after an adverse event, allows you to assess whether the sales process and ongoing management of the product complied with applicable suitability, disclosure, and fiduciary standards. The complexity of structured products means that legal counsel can identify nuances in the term sheet and prospectus that may not be apparent from marketing materials alone. From a practitioner's perspective, investors who wait to consult counsel until losses are substantial often find that critical defenses or counterclaims have been waived or that the statute of limitations for certain claims has begun to run. Moving forward, prioritize preserving all communications and written materials, documenting your investment objectives and risk tolerance at the time of purchase, and seeking legal review if any aspect of the product's performance or the broker's conduct raises concerns about suitability or transparency.
30 Apr, 2026
